Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis CEO on 2Q Profit Beat, Investing in Pipeline...
Bloomberg Markets and Finance-YouTube
Novartis CEO on Q2 earnings beat and patent expiries
Novartis CEO on Q2 earnings beat and patent expiries...
CNBC Television-YouTube
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Zacks
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
Zacks
Market Awaits Crude Inventories Report
Market Awaits Crude Inventories Report.
Zacks
Q2 Earnings Pick Up Steam: GM, MMM, DHI & More
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Zacks
Novartis Q2 2026 Earnings Call Transcript
Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.
Benzinga APIs provide real-time access to earningsread more...
Benzinga
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.